Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 06, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 2,200,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,278.31 pence per share.
- Treasury Shares Held: 340,249,158 shares (representing 5.99% of total voting rights).
- Shares in Issue: 5,681,369,401 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program. Following the transaction on August 06, 2007, the company's Treasury shareholding increased to 340,249,158 shares. The number of shares in issue, used as the denominator for disclosure calculations under the Financial Services Authority's rules, stands at 5,681,369,401.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory conformity statement.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 2,200,000 shares by the price of 1,278.31 pence.
- Confirm the updated percentage of Treasury shares (5.99%) against the total voting rights.
- Check the denominator for disclosure thresholds, which is 5,681,369,401 shares.
- Note that this filing does not contain quarterly or annual financial results.